Effects of tumour necrosis factor α and melphalan on the cytokine production of circulating T cells in patients with cancer

European Journal of Clinical Investigation

Volumn 29, Issue 3, 1999, Pages 256-263

  Stam, T C ^a   Eggermont, A M M ^a   Swaak, A J G ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Lab for Exp/Clin Immunology   (Netherlands)

^c Zuiderziekenhuis   (Netherlands)

Author keywords

Cytokine production intracytoplasmic staining; T cells; TNF ; Whole blood cell culture

Indexed keywords

CD28 ANTIGEN; CYTOKINE; CYTOPLASM PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CIRCULATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOPLASM; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; LIMB PERFUSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE;

EID: 0033014785     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00452.x     Document Type: Article

References (26)

1. 1 Eggermont AMM, Manusama ER, Ten Hagen TLM. Regional application of TNFα in the treatment of cancer: a preclinical-clinical interactive program. J Inflamm 1996; 47: 104-13.
2. 2 Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumour necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996; 274:756-65.
3. 3 Eggermont AMM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumour necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65.
4. 4 Van der Pol T, Van Deventer SJH, Hack CE, et al. Effects on leukocytes after injection of tumour necrosis factor into healthy humans. Blood 1992; 79: 693-8.
5. 5 Van der Pol T, Büller HR, Ten Cate H, et al. Activation of coagulation after administration of tumour necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
6. 6 Van der Pol T, Levi M, Büller HR, et al. Fibrinolytic response to tumour necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-32.
7. 7 Schiller JH, Storer BE, Witt PL, et al. Biological and clinical effects of intravenous tumour necrosis factor-α administered three times weekly. Cancer Res 1991; 51: 1651-8.
8. 8 Jablons DM, Mul JJ, McIntosh JK, et al. IL6/IFN-β-2 as a circulating hormone. J Immunol 1989; 142: 1542-7.
9. 9 Swaak AJG, Liénard D, Schraffordt Koops H, Lejeune FJ, Eggermont AMM. Effects of recombinant rumour necrosis factor (rTNFα) in cancer. Observations on the acute phase reaction and immunoglobulin synthesis after high dose recombinant TNFα administration in cancer patients. Eur J Clin Invest 1993; 23: 812-18.
10. 10 Zwaveling JH, Maring JK, Mulder AB, et al. Effects of hyperthermic isolated limb perfusion with recombinant tumour necrosis factor α and melphalan on the human fibrinolytic system. Cancer Res 1996; 56: 3948-53.
11. 11 Van Roon JA, Van Roy JL, Duits A, Lafeber FP, Bijlsma JW. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann. Rheum. Dis. 1995; 54: 836-840.
12. 12 Van der Meide PH, Dubbeld M, Schellekens H. Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J Immunol Methods 1992; 79: 293-7.
13. 13 Van der Pouw T, Van Kooten C, Rensink HJAM, Aarden LA. Interleukin (IL) 4 production by human T cells; differential regulation of IL4 vs. IL2 production. Eur J Immunol 1992; 22: 1237-41.
14. 14 Stam TC, Jongen-Lavrencic M, Eggermont AMM, Swaak AJG. Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest 1996; 26: 1085-91.
15. 15 Andersson U, Andersson J, Lindfors A, Wagner K, Müller G, Heusser CM. Simultaneous production of interleukin 2, interleukin 4 and interferon-γ by activated human blood lymphocytes. Eur J Immunol 1990; 20: 1591-6.
16. 16 Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehydesaponin procedure. Immunol Rev 1991; 119: 65-93.
17. 17 Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159: 197-207.
18. 18 Scheurich P, Thoma B, Ücer U, Pfizenmaizer K. Immuno-regulatory activity of recombinant human tumour necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T-cell responses. J Immunol 1987; 138: 1786-90.
19. 19 Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen and mitogen-induced human T lymphocyte proliferation by tumour necrosis factor-α. J Immunol 1988; 140: 531-6.
20. 20 Cope AP, Londei M, Randall Chu N, et al. Chronic exposure to rumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor CD-3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 749-60.
21. 21 Gelin JL, Moldawer LL, Iresjö BM, Lundholm KG. The role of the adrenals in the acute phase response to interleukin-1 and tumour necrosis factor-α. J Surg Res 1993; 54: 70-8.
22. 22 Hamid J, Bancewicz J, Brown R, Ward C, Irving MH, Ford WL. The significance of changes in blood lymphocyte populations following surgical operations. Clin Exp Immunol 1984; 56: 49-57.
23. 23 Renard N, Liénard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular highdose tumour necrosis factor alpha (rTNFα). Int J Cancer 1993; 57: 656663.
24. 24 Cavender D, Saegusa Y, Ziff M. Stimulation of endothelial cell binding of lymphocytes by tumour necrosis factor. J Immunol 1987; 139: 1855-60.
25. 25 Carlos TM, Schwanz BR, Kovach NL, et al. Vascular Cell Adhesion Molecule 1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990; 76: 965-70.
26. 26 Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JSS, KyanAung U, Haskard DO. Tumour necrosis factor combines with IL-4 or IFN-γ to selectively enhance endothelial cell adhesiveness for T cells. J Immunol 1991; 146: 592-8.